GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Can Foreign Patients Access Approved Cell Products?

Yes—foreign patients may be able to receive approved cell products in Japan, but approval alone does not guarantee access. First, confirm that the named product is approved for the proposed indication and route. Japan’s approval list specifies these details; it is not an international-patient booking list.000281990.pdf0003 The treating hospital must separately confirm eligibility, current product availability, and whether it can accept your case.

This guide focuses on people travelling to Japan for treatment. Before booking, ask the hospital about medical fitness, payment, interpretation, and follow-up, and confirm entry requirements with the Japanese embassy or consulate. Do not assume the same payment arrangements apply to visitors and foreign residents.

Can Foreign Patients Access Approved Cell Products?

The Pharmaceuticals and Medical Devices Agency (PMDA) list records approvals for specific diseases, not a general category of “stem cell therapy.” Examples include acute graft-versus-host disease (GVHD), traumatic spinal cord injury, Parkinson’s disease, and defined cartilage defects. The list through May 2026 contains no general intravenous (IV) stem cell infusion for arthritis, fatigue, diabetes, or anti-aging.000281990.pdf

Private care and research under the Act on the Safety of Regenerative Medicine (ASRM) follow a different regulatory route. A filed treatment plan is not a product approval and does not establish that a treatment works.0003

What counts as approval

Under the Pharmaceuticals, Medical Devices, and Other Therapeutic Products Act (PMD Act), PMDA reviews product quality, safety, and efficacy, while the Ministry of Health, Labour and Welfare (MHLW) grants approval. The approval has defined indications and instructions for use.000281990.pdf0003

The ASRM route is different. It covers medical practice and research. Providers file plans, but a filed plan is not product approval.0003 The guide to Japan’s regenerative medicine registration and compliance explains that filing route.

Using a product for a different disease or route is not covered by its approved indication. That distinction does not, by itself, settle whether a proposed off-label use is lawful or clinically appropriate.000281990.pdf Conditional and time-limited approval is an approval with additional obligations and unresolved evidence questions, not a trial registration or proof of established benefit. Further data are required, and approval status can change.0001

When a clinic says “approved in Japan,” ask which route, which product, which indication, and which date. Check a PMDA review report, not just a sales email.0004

Check the proposal against the label

Consider a proposal described only as “approved cells for knee arthritis.” The PMDA entry for JACC describes cultured cartilage implanted surgically, with the knee osteoarthritis indication limited to a cartilage defect of at least 2 cm² after conservative treatment has failed. An unnamed IV infusion is not the same product or procedure.000281990.pdf Ask for the product name, imaging findings, and planned route before comparing prices.

Put the hospital’s proposal next to the official product information and compare the diagnosis, cell source, route, and approval status line by line. These are document-based examples, not patient case reports or claims of clinical experience. Only the treating team can assess your records and decide whether treatment is appropriate.

Which products can you ask about

The eight examples below explain product differences; they are not a ranking or a list of currently bookable treatments. Approval dates come from PMDA’s list through May 2026. Historical entries can remain on that list, so ask for current authorization and supply confirmation. HeartSheet is included only as a historical caution, not an access option.000281990.pdf

Selected cell-product approvals and access limits
Product and cell type Approved or historical indication Approval history and evidence Procedure and access limits
Temcell (donor bone marrow mesenchymal stem cells) Acute GVHD after an allogeneic hematopoietic stem cell transplant Approved in 2015. A phase II/III, single-arm study enrolled 25 patients with steroid-refractory grade III/IV acute GVHD. Its primary endpoint, complete response lasting at least 28 days, occurred in 12 patients. The lower 95% confidence limit fell below the 30% historical benchmark. Over 52 weeks, all 25 had adverse events, 22 had serious adverse events, and fatal events occurred in 12.000215658.pdf Specialist transplant care. The initial schedule is eight IV infusions over four weeks; additional treatment depends on response and the prescribing plan.
Stemirac (autologous bone marrow mesenchymal stem cells) Traumatic spinal cord injury, ASIA Impairment Scale (AIS) grade A, B, or C Originally granted conditional and time-limited approval in 2018. In a phase II, open-label study, 17 patients enrolled and 13 received treatment. Twelve of the 13 improved by at least one AIS grade at 220 days after injury. There was no control group. All 13 had post-treatment adverse events; no deaths or serious adverse events occurred in the study.000231946.pdf Bone marrow harvest, cell culture, a single IV infusion, and rehabilitation. Confirm current authorization and the hospital’s timing criteria.
HeartSheet — historical example (autologous skeletal myoblast cell sheet) Historical indication: severe ischemic heart failure inadequately controlled by standard treatment Conditional and time-limited approval in 2015. In the original 7-patient, open-label, uncontrolled study, the primary endpoint assessed left ventricular ejection fraction (LVEF) at 26 weeks: none met the predefined improvement criterion. All seven had adverse events, with serious events in three.000215222.pdf Left thoracotomy. Full approval was rejected in July 2024 because subsequent data did not demonstrate efficacy. Do not treat the 2015 listing as evidence of current access.000272880.pdf
JACC (autologous cultured cartilage) Traumatic cartilage defects or osteochondritis dissecans; knee osteoarthritis with a defect of at least 2 cm² after conservative care fails Full approval, originally in 2012 for traumatic defects and osteochondritis dissecans. The knee osteoarthritis indication was added in May 2025.000281990.pdf Cartilage biopsy, cell culture, implantation, and rehabilitation.
Akuugo (donor bone marrow mesenchymal stem cells modified with Notch-1) Chronic motor paresis after traumatic brain injury Conditional and time-limited approval in July 2024.000281990.pdf Stereotactic brain surgery.
AMCHEPRY (allogeneic induced pluripotent stem (iPS) cell-derived dopaminergic neural progenitors) Motor symptoms of Parkinson’s disease inadequately controlled by conventional drugs, including levodopa Conditional and time-limited approval in March 2026. A phase I/II, open-label, uncontrolled study transplanted seven patients; six were efficacy-evaluable. Primary endpoints assessed adverse events and graft overgrowth on MRI at 24 months. All seven had adverse events, with no deaths or serious adverse events.000281617.pdf Stereotactic transplantation into the putamen. In the study, tacrolimus continued for 52 weeks, then tapered over 12 weeks.
RiHEART (allogeneic iPS cell-derived cardiomyocyte sheet) Severe heart failure from ischemic cardiomyopathy inadequately controlled by standard care Conditional and time-limited approval in March 2026. A phase I/II, open-label, uncontrolled study treated eight patients and followed them for 52 weeks. Two of eight met the primary efficacy endpoint of LVEF improvement at week 26. Seven had adverse events, and five had serious adverse events.000281693.pdf Left thoracotomy and transplantation onto the heart surface, with immunosuppression and follow-up.
Alofisel (donor adipose-derived mesenchymal stem cells) Complex perianal fistula in non-active or mildly active Crohn’s disease after at least one existing medicinal treatment did not work Full approval in 2021 for local injection.000281990.pdf Gastroenterology and surgery. It is not a systemic infusion.

These small studies are not head-to-head comparisons, and they do not establish a success rate for an individual traveller. An adverse event is a medical event during a study, not automatically a reaction caused by the cells. Approval also does not mean the product is made from stem cells: JACC uses cultured cartilage cells. The guide to autologous vs allogeneic stem cells explains the separate distinction between a patient’s own cells and donor cells.

Who can get access

The approved indication is the starting point for on-label treatment, not the entire eligibility decision. Ask the treating specialist to explain how your diagnosis, previous treatment, and procedure risks fit the proposed product.

Knee arthritis

JACC is for traumatic cartilage defects, osteochondritis dissecans, or knee osteoarthritis with a defect of at least 2 cm² after conservative care has failed. A vague “knee arthritis” diagnosis is not enough. JACC is implanted surgically; it is not a simple injection.000281990.pdf

Spinal cord injury

Stemirac’s original approved indication was traumatic spinal cord injury with AIS grade A, B, or C, not stroke or multiple sclerosis. The pivotal study enrolled people within 14 days of injury and required treatment within 54 days. Improvement was assessed at 220 days after injury, not 220 days after infusion. These trial conditions do not demonstrate benefit for an injury sustained years earlier; ask the hospital about current label and timing requirements.000231946.pdf

Parkinson’s disease

AMCHEPRY’s indication does not mean that levodopa must have stopped working completely. The study required at least 30% levodopa responsiveness despite inadequate symptom control. Participants were aged 50 to 69, had Parkinson’s disease for at least five years, and had ON/OFF fluctuations and Hoehn and Yahr stage 3 in the OFF state. Those are study criteria, not a complete substitute for the current label or an individual assessment.000281617.pdf

Heart failure

RiHEART’s indication concerns severe heart failure due to ischemic cardiomyopathy despite standard care, including pharmacotherapy and invasive interventions. It involves surgery, not an outpatient IV infusion.000281693.pdf HeartSheet’s earlier conditional approval must not be presented as an equivalent current treatment option after its full-approval application was rejected.000272880.pdf

Long COVID and anti-aging

The PMDA approval list through May 2026 contains no cell product with an indication for long COVID, fatigue, or anti-aging. A clinic’s ASRM-filed plan is not a product approval for those conditions.000281990.pdf0003

Fitness for the procedure

Ask the hospital to assess infection risk, organ function, anesthesia risks, and your ability to complete follow-up. The guide to indications and contraindications provides questions to discuss with the treating team, not a remote eligibility decision.

How to arrange access

  1. Send your records. Include the exact diagnosis, stage, imaging, pathology, labs, medications, and treatments that have already failed. A hospital cannot judge a one-line description.
  2. Check the product. Look up its name, approved indication, and review report. Ask the hospital for the latest Japanese package insert and authorization status; a historical approval-list entry alone is not enough. If the service is advertised as an approved product but none can be named, do not pay on that basis.000281990.pdf0004
  3. Ask the hospital. Will it accept your case for this specific product, and is supply available? Does it require a referral, translated records, or an interpreter? The MHLW list of institutions accepting foreign patients and the Japan Medical Service Accreditation for International Patients (JMIP) program are starting points. Neither confirms availability of a particular cell product.Newpage_05774Index.php?l=eng The guides to stem cell hospitals in Japan and how to choose one can help organize your questions.
  4. Get the plan and the quote. Ask for the product, cell source, dose, route, number of sessions, admission, anesthesia, drugs, follow-up, and a plan for complications. Check the visa and stay length too. If the cells are processed in Japan, the guide to cell-processing (CPC) facilities explains what to check. Temcell’s infusion course runs four weeks, with follow-up after that; Stemirac adds rehabilitation, and AMCHEPRY and RiHEART involve months of follow-up.000215658.pdf000231946.pdf000281617.pdf000281693.pdf The medical travel guide covers the practical side.
  5. Arrange follow-up at home. Ask for an English discharge summary, imaging, a medication plan, and a named contact for complications after discharge. The guide to the treatment process describes the usual sequence.

What access costs

For a visitor arranging planned treatment, budget on a self-pay basis unless the hospital and insurer confirm coverage in writing. MHLW recommends private insurance for visitors and warns that unpaid medical bills may affect future entry.Newpage_46516 That general travel guidance does not establish coverage for an elective cell procedure; ask specifically about the treatment, complications, and follow-up.

MHLW provides a pricing-method manual for care of foreign visitors; it is not a national price list or a quote for any cell product.Newpage_08838 Ask for a written quote in yen covering cell processing, surgery, admission, medicines, interpretation, follow-up, and possible additional charges. Confirm the deposit and cancellation terms. A published reimbursement price should not be assumed to be your total bill. The guide to stem cell treatment costs in Japan explains the cost categories.

When access is not approval

A provider may describe a treatment as “registered” or “committee-reviewed.” Ask exactly what was reviewed and under which law. Under ASRM, committee review and plan submission do not amount to approval of a commercial product or confirmation of clinical benefit.0003

The same distinction applies to services described on this website: an ASRM plan or clinic page is not independent proof of product approval. Ask for the product identity, plan details where relevant, and evidence for your condition. Research participation is a third decision: trial registration is not approval, and a study’s eligibility rules still apply.

What can still go wrong

The table’s trial summaries concern small, selected groups. Serious events occurred in several studies, while the Temcell review includes deaths in a severely ill post-transplant population. These counts do not establish which events were caused by cells, surgery, immunosuppression, or the underlying illness, and they cannot be compared as product safety rankings.000215658.pdf000215222.pdf000281617.pdf000281693.pdf Ask for a product-specific explanation of adverse reactions, procedure risks, and the monitoring you would need.

Approval is country-specific: the US Food and Drug Administration (FDA) maintains its own list of approved cell and gene therapies. Japanese approval does not establish US approval.Approved cellular and gene therapy products Ask the relevant regulator about any proposed cross-border supply rather than relying on a clinic’s assurances.

Distance matters. A complication that appears after you fly home is harder to manage, so confirm the follow-up plan before you travel. Do not delay standard care for an unproven cell treatment. Treat success rates with caution when they leave out the diagnosis, stage, product, dose, and follow-up. The page on stem cell therapy safety in Japan covers the questions to ask.

Check access first

Questions to ask before you pay
Question A good answer Warning sign
What exactly is the product? A named product, current label, and confirmed authorization Only “stem cells” or an old approval date
What is it approved for? A specific disease and patient group “Many conditions” or “your whole body”
Is the approval full or conditional? A clear status and date “Approved” with no details
Which hospital and doctor? A named institution and physician A hotel address or a sales office
What will it cost, and how long will I stay? An itemized quote in yen and a schedule One package price, or “a few days” for surgery
What is the plan for complications, and what is the evidence? A written contact plan and a PMDA report No after-hours contact, or testimonials only

Can you get access?

Your next step is a written assessment from a hospital that actually provides the named product. Ask it to confirm the indication, current availability, treatment schedule, full costs, and responsibility for complications after you return home. Money and a matching diagnosis alone do not secure a place.

If the proposed approved product is not suitable or available, discuss standard care, a relevant clinical trial, or another specialist opinion. Do not substitute an unrelated infusion simply because it is easier to book.

Not sure whether your diagnosis fits?

Ask what information is needed to clarify your treatment enquiry. Contacting us does not confirm eligibility, referral, product availability, or treatment.

Ask about your case

This article is educational, not an individual medical assessment. The approval-list snapshot covers entries through May 2026; sources were reviewed on 24 October 2026, with the PMDA review-report index and HeartSheet decision checked again on 27 October 2026. No hospital place, price, or current product supply has been confirmed. Verify the latest Japanese label and availability with the treating hospital before making travel or payment arrangements.